P-Glycoprotein Inhibitors [MoA] class drugs

223 results

  • addyi - flibanserin tablet, film coated

    (Flibanserin)
    Sprout Pharmaceuticals, Inc.
    Addyi treats acquired, generalized hypoactive sexual desire disorder (HSDD) in women under 65 whose low sexual desire causes marked distress and is not due to a medical condition, relationship problems, or medications.
    Medication Details
    Drug Interactions

  • akynzeo - netupitant and palonosetron capsule

    (Netupitant And Palonosetron)
    Helsinn Therapeutics (U.S.), Inc.
    AKYNZEO (palonosetron/netupitant) is used with dexamethasone in adults to prevent acute and delayed nausea and vomiting from cancer chemotherapy, including highly emetogenic regimens. Available as capsules for broad chemotherapy use and as an injection for highly emetogenic chemotherapy only.
    Medication Details
    Drug Interactions

  • alyftrek - vanzacaftor, tezacaftor, and deutivacaftor tablet, film coated

    (Vanzacaftor, Tezacaftor, And Deutivacaftor)
    Vertex Pharmaceuticals Incorporated
    Alyftrek treats cystic fibrosis (CF) in adults and children 6 years and older with at least one CFTR gene variant responsive to treatment or that produces CFTR protein.
    Medication Details
    Drug Interactions

  • ayvakit - avapritinib tablet, film coated

    (Avapritinib)
    Blueprint Medicines Corporation
    Ayvakit treats adults with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations (including D842V), advanced systemic mastocytosis (ASM, SM-AHN, mast cell leukemia), and indolent systemic mastocytosis. Not recommended when platelet counts are below 50 × 10⁹/L.
    Medication Details
    Drug Interactions

  • balversa - erdafitinib tablet, film coated

    (Erdafitinib)
    Janssen Products Lp
    BALVERSA treats adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease progressed after at least one prior systemic therapy. Patient selection requires an FDA-approved companion diagnostic. Not recommended for patients eligible for PD-1/PD-L1 inhibitor therapy who have not yet received it.
    Medication Details
    Drug Interactions

  • belsomra - suvorexant tablet, film coated

    (Suvorexant)
    Merck Sharp & Dohme Llc
    Belsomra (suvorexant) is indicated for the treatment of insomnia in adults experiencing difficulty falling asleep and/or staying asleep.
    Medication Details
    Drug Interactions

  • brilinta - ticagrelor tablet

    (Ticagrelor)
    Astrazeneca Pharmaceuticals Lp
    Brilinta reduces the risk of cardiovascular death, heart attack, and stroke in patients with acute coronary syndrome or prior heart attack. It also lowers the risk of first heart attack or stroke in high-risk coronary artery disease patients, and reduces stroke risk after mild ischemic stroke or high-risk TIA.
    Medication Details
    Drug Interactions